New scanner used for brain tumour patients trialled in world-first
A 'pioneering' new scanner derived from MRI technology could be used to track brain cancer spread and lead to improved treatment for patients, researchers have said.
Scientists at the University of Aberdeen and NHS Grampian have been awarded £350,000 of Scottish Government funding to generate never-before-seen images of glioblastoma brain tumours.
The technology is hoped to potentially improve treatment and quality of life for patients, by investigating a new way to scan glioblastoma brain tumours – the most common and aggressive type, with more than 3,000 new patients in the UK diagnosed each year.
Half of all patients die within 15 months of diagnosis even after extensive surgery, radiotherapy and chemotherapy.
Field cycling imaging (FCI) is a new and specialist type of low-field MRI scan pioneered in Aberdeen and has already been found to be effective in detecting tumours in breast tissue and brain damage in stroke patients.
It is hoped it can now be used to help brain tumour patients.
MRI scanners were invented at the University of Aberdeen 50 years ago, but the new FCI scanner is the only one of its type used on patients anywhere in the world.
The FCI derives from MRI but can work at low and ultra-low magnetic fields which means it is capable of seeing how organs are affected by diseases in ways that were previously not possible, and can vary the strength of the magnetic field during the patient's scan – acting like multiple scanners and extracting more information about the tissues.
The new technology can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some patients.
The team of doctors and scientists involved will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy.
It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and 'pseudo-progression' which looks like tumour but is not cancerous tissue, which could improve care and quality of life.
Professor Anne Kiltie, Friends of ANCHOR chair in clinical oncology at the University of Aberdeen, who is leading the study said: 'We already have evidence that FCI is effective in detecting tumours in breast tissue and brain damage in patients following a stroke.
'Applying this exciting new technology to glioblastoma patients could give us a much more accurate and detailed picture of what is going on in their brain.
'If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy.
'Also, being able to verify that a patient has pseudo-progression will prevent effective chemotherapy being stopped too early, because it was thought that the tumour has progressed, thus worsening prognosis.
'Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients.
'Importantly, having a reliable method to identify progressive disease will allow development and more precise evaluation of emerging potential treatments. This is of particular importance as patients currently have a limited choice of treatments for combating their cancer.
'Ultimately, this study and related future work will improve quality, effectiveness and healthcare cost-effectiveness in the treatment of glioblastoma patients across Scotland and beyond.'
Sarah-Jane Hogg, chief executive at Friends of ANCHOR, added: 'This is a really promising development and another example of the pioneering work coming out of the University of Aberdeen.
'Professor Kiltie's role at the University is fully funded by Friends of ANCHOR through our Dream Big appeal, and our thanks go to our donors and fundraisers for the part they've played in supporting this work.'
A spokesperson for The Brain Tumour Charity said: 'This pioneering technology is a promising step forward for people who have been diagnosed with the most aggressive type of brain tumour.
'It's positive news in contrast to the accounts we often hear about delays to diagnosis, limited treatment options, and the struggle to get vital innovations to the NHS front line.
'We welcome this, and The Brain Tumour Charity will continue working with clinicians and policymakers in Scotland – and the rest of the UK – to help bring advances to patients more quickly.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Blood test can detect cancer 18 months before symptoms appear
A new blood test means it is now possible to detect cancer up to 18 months before symptoms even appear. Test for Cancer has launched the HrC Genomics blood test, a non-invasive screening tool designed to spot cancer before it becomes symptomatic, reducing the need for invasive procedures like tissue biopsies. With cancer among the world's leading causes of death, early detection remains one of the most effective ways to improve outcomes. But many cancers are diagnosed too late, when treatment options are more limited and survival rates are lower. Test for Cancer says its new test can change that. By identifying specific stem cells that begin circulating when cancer is present, even before symptoms emerge, the HrC Genomics test offers a way to screen for cancer much earlier than standard approaches allow. READ MORE: Cardiologists name two foods that lower cholesterol 'just like statins' READ MORE: Neurologist says you can cut cholesterol, blood pressure and dementia risk in 20 minutes According to the organisation, these cells, known as pluripotent progenitor stem cells, can be detected in the blood as early as 12 to 18 months before any signs of illness. That early window gives patients and doctors more time to intervene and improves the chances of successful treatment. The test is available to adults of all ages and is not limited by gender or family history, making it a potentially powerful screening option for people who might not otherwise qualify for routine checks. Test for Cancer says its mission is to make early cancer detection more widely accessible, helping more people take control of their health and catch cancer before it advances.
Yahoo
an hour ago
- Yahoo
MIT's high-tech ‘bubble wrap' turns air into safe drinking water — even in Death Valley
When you buy through links on our articles, Future and its syndication partners may earn a commission. MIT researchers have created a high-tech 'bubble wrap' capable of collecting safe drinking water directly from the air — even in Death Valley, the driest desert in North America. The new water harvester is a major step towards providing safe, accessible drinking water to people across the globe — and works wherever you may find water vapor in the air, scientists said in a new study published June 11 in the journal Nature Water. The water harvester is made from hydrogel (a highly water-absorbent material) that is enclosed between two layers of glass — much like a window. At night, the device absorbs water vapor from the atmosphere. During the day, the water condenses on the glass thanks to a coating that keeps the glass cool. The liquid water then drips down the glass and is collected in a system of tubes. The hydrogel is formed into a special shape, a series of domes resembling a sheet of bubble wrap that swells up when absorbing water vapor. The domes increase the material's surface area, which increases the amount of water it can hold. Researchers tested the new device for a week in Death Valley, a unique desert valley spanning across parts of California and Nevada. It's the hottest place in the world and the driest place in North America. Related: 2 billion people could face chaotic and 'irreversible' shift in rainfall patterns if warming continues It produced about a quarter to two-thirds of a cup of water every day (57-161.5 milliliters). In more humid areas, the device should produce even more water. This design is a lot more effective than some previous attempts to collect drinking water from air, all without needing electricity to power it, MIT representatives said in a statement. The researchers also solved another long-standing problem with the quality of water collected using hydrogel designs. Lithium salts, added to the hydrogel to increase water absorption, normally leak into the water in similar designs, rendering the water unsafe to drink without further processing. This new design includes a salt stabilizer called glycerol which reduces the leakage below 0.06 ppm, the US Geological Survey's estimate for how much lithium salt can be present in groundwater before it might be unsafe to drink. RELATED STORIES —Stabbed, cut, attacked, twisted — scientists subject new stretchable battery to extreme torture, and it retained 90% of its capacity —Ancient groundwater records reveal worrying forecast for US Southwest —Scientists invent photosynthetic 'living' material that sucks CO2 out of the atmosphere While one panel might not produce enough water to sustain an entire household, they don't take up much space — which means multiple panels could be set up for a single household. The researchers estimate that using eight 3 foot by 6 foot (1 m by 2 m) panels could be enough to supply households anywhere that there isn't easy access to safe drinking water. Compared to the costs of bottled water in the US, the device could pay for itself in less than a month and last at least one year. 'We imagine that you could one day deploy an array of these panels, and the footprint is very small because they are all vertical,' Xuanhe Zhao, one of the paper's authors and a professor of both MIT's mechanical engineering and civil and environmental engineering departments, said in the statement. 'Now people can build it even larger, or make it into parallel panels, to supply drinking water to people and achieve real impact.' The team plans to test the panels in additional resource-limited environments to learn more about the device's performance under different conditions.
Yahoo
2 hours ago
- Yahoo
Major organizational dysfunction led to death of senior in Châteauguay hospital: Quebec coroner
A coroner's report is shedding light on the death of an 80 year-old-man who died at Anna-Laberge Hospital in 2023 of natural causes, but in a context of "significant organizational dysfunction." Yvon Brossoit died from heart failure after waiting in the emergency room of the Châteauguay, Que., hospital for over 11 hours without being re-evaluated. On Nov. 29, 2023, he presented himself at the hospital due to abdominal pain. He was classified as a code 3 in triage, which means he should have been reassessed every 30 minutes while waiting to see a doctor, coroner Jean Brochu wrote. But that never happened. Brossoit's condition deteriorated and he died 11 hours later from a ruptured abdominal aneurysm without having been seen by a medical professional. In his report published Saturday, Brochu indicated that significant organizational dysfunction is partly to blame for Brossoit's death. Brochu said certain precautions, that would have placed Brossoit in a separate area with a cardiac monitor, were not applied. And the emergency room was operating at 191 per cent capacity on the day he died. Majority of recommendations already in place, says CISSS In his report, Brochu made a number of recommendations, including setting up a computer case management system in the emergency room and assigning a nurse to patients who are waiting on stretchers. An investigation carried out by the team in charge of quality, evaluation, performance and ethics following Brossoit's death concluded that "the organizational context, the organization of resources and the operation of the emergency department on Nov. 29, 2023 at Anna-Laberge Hospital certainly had an impact on the evolution of Mr. Brossoit's condition and on the possibility of directing him to the required treatment area." The investigation also showed that the criteria for referring patients to the emergency department – implemented in February 2023 during a visit by a team from the Ministry of Health and Social Services – were not in place on that day. "The implementation of these criteria would have allowed Mr. Brossoit to be directed to a stretcher area with a heart monitor and not to be returned to the waiting room," read Brochu's report. The office of Quebec's health minister, in an email sent to CBC, said it would leave it to the hospital to comment on the situation. The CISSS de la Montérégie-Ouest, the agency that manages the hospital, said it has reviewed the report and implemented the "vast majority" of recommendations. "There has been a 20 per cent reduction in ER occupancy, a 20 per cent increase in the number of admissions, a reduction in the number of ambulance patients and a significant drop in the average length of stay," wrote Jade St-Jean, a spokesperson for the CISSS de la Montérégie-Ouest, in a statement. "Among the actions put in place are the implementation of a hospital flow management centre, the addition of a computerized management system in the emergency department [and] improvements to the reassessment process."
